Efficacy of Tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: A randomized clinical trial

JAMA

Volumn 281, Issue 19, 1999, Pages 1797-1804

  Turner, Ronald B ^a   Wecker, Margaret T ^b   Pohl, Gerhardt ^b   Witek, Theodore J ^b   McNally, Eugene ^b   St George, Roger ^b   Winther, Birgit ^c   Hayden, Frederick G ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MANNITOL; NOSE SPRAY; PLACEBO; RECOMBINANT INTERCELLULAR ADHESION MOLECULE 1; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EXPERIMENTAL INFECTION; FEMALE; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NOSE IRRITATION; NOSE MUCUS; POWDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOVIRUS; SEROCONVERSION; SYMPTOMATOLOGY; VIRUS INFECTION; VIRUS ISOLATION;

EID: 0033583710     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.19.1797     Document Type: Article

References (34)

1. Abraham G, Colonno RJ. Many rhinovirus serotypes share the same cellular receptor. J Virol. 1984; 51:340-345.
2. Greve JM, Davis G, Meyer AM, et al. The major human rhinovirus receptor is ICAM-1. Cell. 1989;56: 839-847.
3. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA. A cell adhesion molecule, ICAM-1 is the major surface receptor for rhinoviruses. Cell. 1989;56:849-853.
4. Hayden FG, Gwaltney JM Jr, Colonno RJ. Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res. 1988;9:233-247.
5. Crump CE, Arruda E, Hayden FG. In vitro inhibitory activity of soluble ICAM-1 for the numbered serotypes of human rhinovirus. Antiviral Chem Chemother. 1993;4:323-327.
6. Marlin SD, Staunton DE, Springer TA, Stratowa C, Sommergruber W, Merluzzi VJ. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature. 1990;344:70-72.
7. Grunberg K, Timmers MC, Smits HH, et al. Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin Exp Allergy. 1997;27:36-45.
8. Teran LM, Johnston SL, Schroder J-M, Church MK, Holgate ST. Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma. Am J Respir Crit Care Med. 1997; 155:1362-1366.
9. Turner RB, Weingand KW, Yeh C-H, Leedy D. Association between nasal secretion interleukin-8 concentration and symptom severity in experimental rhinovirus colds. Clin Infect Dis. 1998;26:840-846.
10. Zhu Z, Tang WL, Gwaltney JM, Elias JA. Rhinovirus stimulation of interleukin-8 in vivo and in vitro: role of NF-Kappa-β. Am J Physiol. 1997;17:L814-L824.
11. Zhu Z, Tang W, Ray A, et al. Rhinovirus stimulation of interleukin-6 in vivo and in vitro: evidence for nuclear factor kB-dependent transcriptional activation. J Clin Invest 1996;97:421-430.
12. Gwaltney JM Jr, Hendley JO, Hayden FG, et al. Updated recommendations for safety testing of viral inocula used in volunteer experiments on rhinovirus colds. Prog Med Virol. 1992;39:256-263.
13. Arruda E, Crump CE, Rollins BS, Ohlin A, Hayden FC. Comparative susceptibilities of human embryonic fibroblasts and HeLa cells for isolation of human rhinoviruses. J Clin Microb. 1996;34:1277-1279.
14. Gwaltney JM Jr, Colonno RJ, Hamparian VV, Turner RB. Rhinoviruses. In: Schmidt NJ, Emmons RW, eds. Diagnostic Procedures for Viral Rickettsial and Chlamydial Infections. 6th ed. Washington, DC: American Public Health Association; 1989: 579-614.
15. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions, I: the common cold as a clinical entity. Arch Intern Med. 1958;101:267-278.
16. Hendley JO, Edmonson WP Jr, Gwaltney JM Jr. Relation between naturally acquired immunity and infectivity of two rhinoviruses in volunteers. J Infect Dis. 1972;125:243-248.
17. Huguenel ED, Cohn D, Dockum DP, et al. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1. Am J Respir Crit Care Med. 1997;155:1206-1210.
18. Zerial A, Werner GH, Phillpotts RJ, Willmann JS, Higgins PG, Tyrrell DA. Studies on 44 081 RP, a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob Agents Chemother. 1985;27: 846-850.
19. Woods MG, Diana GD, Rogge MC, Otto MJ, Dutko FJ, McKinlay MA. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989;33: 2069-2074.
20. Rozhon E, Cox S, Buontempo P, et al. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res. 1993;21:15-35.
21. Kenny MT, Dulworth JK, Torney HL. In vitro and in vivo antipicornavirus activity of some phenoxypyridinecarbonitriles. Antimicrob Agents Chemother. 1985; 28:745-750.
22. Ishitsuka H, Ninomiya YT, Ohsawa C, Fujiu M, Suhara Y. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410. Antimicrob Agents Chemother. 1982;22:617-621.
23. DeLong DC, Reed SE. Inhibition of rhinovirus replication in organ culture by a potential antiviral drug. J Infect Dis. 1980;141:87-91.
24. Came PE, Schafer TW, Silver GH. Sensitivity of rhinoviruses to human leukocyte and fibroblast interferons. J Infect Dis. 1976;133:A136-A139.
25. Andries K, Dewindt B, Snoeks J, et al. In vitro activity of pirodavir (R 77975), a substituted phenoxypyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 1992;36: 100-107.
26. Barrow GI, Higgins PG, Tyrrell DAJ, Andries K. An appraisal of the efficacy of the antiviral R 61837 in rhinovirus infections in human volunteers. Antiviral Chem Chemother. 1990;1:279-283.
27. Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother. 1992;36:727-732.
28. Douglas RM, Moore BW, Miles HB, et al. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med. 1986;314:65-70.
29. Hayden FG, Gwaltney JM Jr. Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis. 1983;148:543-550.
30. Hayden FG, Gwaltney JM Jr. Intranasal interferon-alpha 2 treatment of experimental rhinovirus colds. J Infect Dis. 1984;150:174-180.
31. Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med. 1986; 314:71-75.
32. Higgins PG, Al-Nakib W, Willman J, Tyrrell DA. Interferon-beta seras prophylaxis against experimental rhinovirus infection in volunteers. J Interferon Cytokine Res. 1986;6:153-159.
33. Monto AS, Shope TC, Schwartz SA, Albrecht JK. Intranasal interferon-α 2b for seasonal prophylaxis of respiratory infection. J Infect Dis. 1986;154:128-133.
34. Harris JM II, Gwaltney JM Jr. Incubation periods of experimental rhinovirus infection and illness. Clin Infect Dis. 1996;23:1287-1290.